Feng Zhou, Hu Xiaoying, Qu Weiying, Zhu Xiaoqin, Lu Jiaying, Huang Zhongdi, Zhao Lin, Chen Pei
Department of Hematology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Evid Based Complement Alternat Med. 2021 Sep 30;2021:6655848. doi: 10.1155/2021/6655848. eCollection 2021.
To explore the clinical efficacy and mechanism of compound Shenlu granule (SLG) treatment in patients with aplastic anemia (AA).
A total of 89 AA patients were randomly divided into an SLG supportive group (group A, = 44) and a control group (group B, = 45) while continuing Western medical management. After 6 months, hemograms, traditional Chinese medicine (TCM) syndrome scores, and overall clinical efficacy rate were assessed. Serum metabolomics characteristics were observed using ultraperformance liquid chromatography-mass spectrometry after SLG intervention.
The levels of red blood cell (RBC), hemoglobin (Hb), and platelet (PLT) were increased in both groups after treatment for 6 months ( < 0.05), and in group A, the elevation of PLT became much more significant ( < 0.01). The TCM syndrome score was lower in group A than in group B after treatment ( < 0.05). Metabolomics data showed a significant difference in the patients using SLG after 6 months, and 14 biomarkers were identified.
SLG supportive treatment showed positive results in patients with AA, and metabolomics data indicated that SLG influenced aminoacyl-tRNA biosynthesis and glycerophospholipid metabolism to gradually return to normal.
探讨复方参鹿颗粒（SLG）治疗再生障碍性贫血（AA）患者的临床疗效及作用机制。
将89例AA患者随机分为SLG支持治疗组（A组，n = 44）和对照组（B组，n = 45），同时继续西医治疗。6个月后，评估血常规、中医证候评分及总体临床有效率。SLG干预后，采用超高效液相色谱-质谱联用技术观察血清代谢组学特征。
两组治疗6个月后红细胞（RBC）、血红蛋白（Hb）及血小板（PLT）水平均升高（P < 0.05），且A组PLT升高更为显著（P < 0.01）。治疗后A组中医证候评分低于B组（P < 0.05）。代谢组学数据显示，使用SLG治疗6个月后的患者存在显著差异，共鉴定出14种生物标志物。
SLG支持治疗对AA患者有积极效果，代谢组学数据表明SLG影响氨酰-tRNA生物合成及甘油磷脂代谢，使其逐渐恢复正常。
